Tcr2 Therapeutics Inc (TCRR) Receives $30.75 Average Price Target from Brokerages

Shares of Tcr2 Therapeutics Inc (NASDAQ:TCRR) have earned a consensus rating of “Buy” from the six research firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $30.75.

TCRR has been the subject of several recent analyst reports. Svb Leerink initiated coverage on shares of Tcr2 Therapeutics in a report on Monday, March 11th. They issued an “outperform” rating and a $27.00 target price for the company. Zacks Investment Research lowered shares of Tcr2 Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 14th. Wedbush began coverage on shares of Tcr2 Therapeutics in a research report on Monday, March 11th. They issued an “outperform” rating and a $28.00 price target for the company. They noted that the move was a valuation call. Leerink Swann began coverage on shares of Tcr2 Therapeutics in a research report on Monday, March 11th. They issued an “outperform” rating for the company. Finally, BMO Capital Markets began coverage on shares of Tcr2 Therapeutics in a research report on Monday, March 11th. They issued an “outperform” rating and a $37.00 price target for the company.

TCRR traded up $0.18 on Tuesday, reaching $14.23. The company had a trading volume of 29,006 shares, compared to its average volume of 45,180. The firm has a market capitalization of $348.87 million and a PE ratio of -0.14. Tcr2 Therapeutics has a one year low of $13.51 and a one year high of $25.47.

Tcr2 Therapeutics (NASDAQ:TCRR) last announced its earnings results on Monday, May 13th. The company reported ($4.85) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.38) by ($4.47). As a group, research analysts anticipate that Tcr2 Therapeutics will post -6.08 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of TCRR. MPM Asset Management LLC purchased a new stake in shares of Tcr2 Therapeutics in the first quarter worth approximately $67,192,000. Redmile Group LLC purchased a new stake in shares of Tcr2 Therapeutics in the first quarter worth approximately $28,686,000. ArrowMark Colorado Holdings LLC purchased a new stake in shares of Tcr2 Therapeutics in the first quarter worth approximately $8,204,000. Hillhouse Capital Management LTD. purchased a new stake in shares of Tcr2 Therapeutics in the first quarter worth approximately $5,628,000. Finally, JPMorgan Chase & Co. purchased a new stake in shares of Tcr2 Therapeutics in the first quarter worth approximately $3,463,000. 1.04% of the stock is owned by institutional investors and hedge funds.

About Tcr2 Therapeutics

TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.

Recommended Story: CBOE Russell 2000® Volatility Index

Analyst Recommendations for Tcr2 Therapeutics (NASDAQ:TCRR)

Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.